Dynavax Technologies. has filed a patent for a method to determine CpG ODN concentration in vaccine formulations containing alum and antigen. The method involves a colorimetric assay measuring total phosphorus, providing a precise and efficient way to analyze vaccine components. GlobalData’s report on Dynavax Technologies gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Dynavax Technologies Corp - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Dynavax Technologies, Personalized cancer vaccines was a key innovation area identified from patents. Dynavax Technologies's grant share as of January 2024 was 45%. Grant share is based on the ratio of number of grants to total number of patents.

A patent application (Publication Number: US20240027434A1) discloses a method for determining the concentration of CpG-containing oligodeoxynucleotide (CpG ODN) in a formulation. The method involves mixing sulfuric acid and ammonium persulfate with a formulation containing aluminum hydroxide particles (alum), an antigen bound to the alum, and the CpG ODN. This mixture is then processed to convert organic phosphorus in the CpG ODN to orthophosphate, which is further reacted to form an antimony-phosphate-molybdate complex. The concentration of total phosphorus in this complex is determined by measuring absorbance at 650 nm and calculating it from a standard curve. The concentration of CpG ODN in the formulation is then determined based on the total phosphorus concentration.

Furthermore, the method includes specific steps such as boiling, cooling, and filtering the mixture, conducting steps in acid-washed glassware, and measuring absorbance within a specific time frame. The formulation may contain saline or a buffer with a pH range of 6 to 9, which can be a phosphate buffer. The CpG ODN used in the method is specified to be 8 to 50 nucleotides in length with a CpG motif, and it may include modified nucleosides or phosphorothioate linkages. The antigen in the formulation can be a viral, bacterial, fungal, or tumor antigen, including fusion proteins with multiple polypeptides. The preparation of the formulation involves adding the antigen to the alum first, followed by the CpG ODN, or adding both simultaneously. These detailed steps and components contribute to a precise and reliable method for determining the concentration of CpG ODN in a formulation, which can have applications in various fields such as vaccine development and immunotherapy.

To know more about GlobalData’s detailed insights on Dynavax Technologies, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies